[Form 4] LIGAND PHARMACEUTICALS INC Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Ligand Pharmaceuticals’ Chief Financial Officer, Octavio Espinoza, reported multiple stock option exercises on December 16, 2025. He acquired a total of 2,381 shares of common stock through option exercises at strike prices of $52.84, $57.22, $63.62, $92.65, and $103.42 per share. Following these transactions, he directly beneficially owned 28,567 shares of Ligand common stock. The exercised options were granted under several employee stock option awards with vesting schedules running through 2025 and expiration dates between 2028 and 2032.
Positive
- None.
Negative
- None.
Insider Trade Summary
2,381 shares exercised/converted
Mixed
10 txns
Insider
Espinoza Octavio
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 1,194 | $0.00 | -- |
| Exercise | Employee Stock Option (right to buy) | 69 | $0.00 | -- |
| Exercise | Employee Stock Option (right to buy) | 285 | $0.00 | -- |
| Exercise | Employee Stock Option (right to buy) | 652 | $0.00 | -- |
| Exercise | Employee Stock Option (right to buy) | 181 | $0.00 | -- |
| Exercise | Common Stock | 1,194 | $52.84 | $63K |
| Exercise | Common Stock | 69 | $57.22 | $4K |
| Exercise | Common Stock | 285 | $63.62 | $18K |
| Exercise | Common Stock | 652 | $92.65 | $60K |
| Exercise | Common Stock | 181 | $103.42 | $19K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 972 shares (Direct);
Common Stock — 27,380 shares (Direct)
Footnotes (1)
- The stock option vests as to approximately 55% of the underlying shares in 12 substantially equal monthly installments beginning on January 5, 2025, and approximately 45% of the underlying shares in two substantially equal monthly installments thereafter. As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter. The stock option is fully vested and exercisable. The stock option vests as to 50% of the underlying shares on January 3, 2025 and as to the remaining on February 3, 2025.
